Intuitive Surgical stock gains as analysts see upside after Q2 growth

Intuitive Surgical stock (ISIN US46120E6023) is trading near USD 393 on Nasdaq, with recent data showing a closing price of USD 393.33 on September 18, 2026, and a consensus analyst price target of USD 508.68 that implies roughly 29.3% upside from that level.

Analysts underline upside potential

According to MarketBeat on September 18, 2026, Intuitive Surgical stock closed at USD 393.33 on Nasdaq, with an average analyst rating score of 2.68 based on 22 buy, 8 hold and 1 sell recommendations.

The same overview reports a consensus price target of USD 508.68 for Intuitive Surgical stock, representing about 29.3% upside from the closing price of USD 393.33 on September 18, 2026, underscoring that analysts still see room for appreciation despite the recent share-price decline from the start of the year.

Q2 2026 expectations point to double-digit growth

For Q2 2026, analysts expect Intuitive Surgical to deliver earnings per share between USD 2.48 and USD 2.50, compared with EPS of USD 2.19 in Q2 2025, which would mark an increase of roughly 14% year on year, according to an earnings preview by TradingKey dated July 16, 2026.

The same preview notes that revenue for Q2 2026 is anticipated in a range of USD 2.81 billion to USD 2.82 billion versus USD 2.44 billion in Q2 2025, implying growth of roughly 15% to 16% year on year, which highlights continued demand for the company’s robotic-assisted surgery platforms, including the da Vinci family of systems.

TradingKey also points out that Intuitive Surgical has beaten earnings expectations for the past four quarters, suggesting a history of delivering results above consensus, which can support valuation levels even after a share-price pullback from earlier highs.

Stock performance and valuation context

MarketBeat notes that Intuitive Surgical’s stock was trading at USD 566.36 at the start of 2026 and has since declined by about 30.6% to USD 393.33, meaning the current level is roughly one third below where the shares began the year, even as forward-looking earnings and revenue estimates continue to show double-digit growth.

On September 21, 2026, trading data compiled by Robinhood shows Intuitive Surgical stock changing hands around USD 393.59 with a day’s high of USD 394.60 and a low of USD 379.50 during the September 20, 2026 session, alongside a market capitalization of approximately USD 138.91 billion and an active volume of 4.93 million shares compared with a 2.83 million average.

The Robinhood overview also reports that over the past 52 weeks Intuitive Surgical stock has traded between a high of USD 603.88 and a low of USD 328.57, placing the current price zone of about USD 393 in the lower half of that range and giving investors context on how far the share price remains below its 52-week peak.

Recent rating actions and targets

Analyst actions over recent months have helped shape the current view on Intuitive Surgical stock. According to PriceTargets.com on September 21, 2026, BTIG Research reiterated its Buy rating on Intuitive Surgical on September 8, 2026, with a price target of USD 469, while Oppenheimer upgraded the stock from Market Perform to Outperform on August 12, 2026 and set a price target of USD 500.

The same analyst compilation lists HSBC as having downgraded Intuitive Surgical stock from Buy to Hold with a price target of USD 391 on July 30, 2026, placing that target almost exactly at the current trading level near USD 393, while UBS Group adjusted its Intuitive Surgical price objective from USD 550 to USD 500 in late July 2026 as part of an upgrade from Neutral to Buy.

This mix of Buy, Hold and one Sell recommendation, together with price targets spanning roughly USD 357 to USD 550, frames a risk-reward profile where some houses see limited upside from current levels and others expect the stock to move materially higher as earnings and revenue grow.

Operational developments support long-term story

While the core of the investment case around Intuitive Surgical stock rests on financial results and procedure growth, recent product and geographic developments also play into the narrative. On September 19, 2026, Intuitive announced the introduction of its latest-generation da Vinci 5 robotic-assisted surgical system in India, marking a further expansion of its robotic surgery footprint in a key emerging market, as reported by BusinessWire India via Webindia123.

The report explains that da Vinci 5 builds on the design of the established da Vinci Xi system and incorporates more than 150 enhancements, including significantly higher computing power and new sensors and software, which are intended to provide surgeons with enhanced surgical senses and operational efficiency and to increase the autonomy and actionable insights available in the operating room.

For investors watching Intuitive Surgical stock, such platform upgrades and regional launches are a strategic backdrop to the financial figures, as they can help drive future procedure volumes and system placements that feed into revenue and recurring instrument and accessory sales.

Stock level and investor takeaway

As of the close on September 18, 2026, Intuitive Surgical stock stood at USD 393.33 on Nasdaq, with the latest 52-week range from USD 328.57 to USD 603.88 and a market capitalization around USD 138.91 billion as of September 20, 2026, placing the shares well below their 52-week high even as analysts project Q2 2026 revenue growth of roughly 15% year on year and maintain an average price target above USD 500.

More news and analyses on Intuitive Surgical stock